Australis Capital Inc AUSAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.05
- Bid/Ask
- $0.01 / $0.02
- Market Cap
- $2.35 Mil
- Volume/Avg
- 659 / 142,330
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://ausa-corp.com
Valuation
|
Metric
|
AUSAF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AUSAF
Financial Strength
|
Metric
|
AUSAF
|
|---|---|
Quick Ratio | 1.17 |
Current Ratio | 2.07 |
Interest Coverage | −81.36 |
Quick Ratio
AUSAF
Profitability
|
Metric
|
AUSAF
|
|---|---|
Return on Assets (Normalized) | −11.25% |
Return on Equity (Normalized) | −19.17% |
Return on Invested Capital (Normalized) | −13.59% |
Return on Assets
AUSAF
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Slmnzhwmkw | Chhvjdn | $78.4 Bil | |
ZTS
| Zoetis Inc Class A | Rhxtglxpr | Pnvxs | $77.9 Bil | |
HLN
| Haleon PLC ADR | Ybjptglh | Tjkj | $37.6 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Pmzkbzvc | Qdk | $18.8 Bil | |
VTRS
| Viatris Inc | Snwgztr | Tch | $12.5 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mdyrxhvyr | Dhlcb | $12.0 Bil | |
CTLT
| Catalent Inc | Xjrclkqkg | Dvvvxy | $9.7 Bil | |
PRGO
| Perrigo Co PLC | Rxgfbjqd | Thjmt | $3.8 Bil | |
CURLF
| Curaleaf Holdings Inc | Twrgpzh | Nthcw | $3.4 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Cyjqnyrmj | Mpctl | $3.2 Bil |